Below are the most recent publications written about "Hepatocyte Growth Factor" by people in Profiles.
-
Goh KY, Tham SC, Cheng TY, Nadarajah R, Goh RCH, Wong SL, Ho TH, Chew GK, Tan AWK, Rajesh H, Chua HL, Yong TT, Yu SL, Kang JM, Lau KW, Tay AZE, Mantoo S, Busmanis I, Chew SH, Lim TYK, Wong WL, Ng QJ, Wang J, Tay SK, Cheok CF, Lim DW, Lim EH. Cell Migration in Endometriosis Responds to Omentum-Derived Molecular Cues Similar to Ovarian Cancer. Int J Mol Sci. 2025 Feb 20; 26(5).
-
Rossi N, Lee KA, Bermudez MV, Visconti A, Thomas AM, Bolte LA, Bj?rk JR, de Ruijter LK, Newton-Bishop J, Harland M, Shaw HM, Harries M, Sacco J, Board R, Lorigan P, de Vries EGE, Segata N, Taams L, Papa S, Spector TD, Nathan P, Weersma RK, Hospers GAP, Fehrmann RSN, Bataille V, Falchi M. Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma. EBioMedicine. 2022 Sep; 83:104235.
-
Cao Z, Ye T, Sun Y, Ji G, Shido K, Chen Y, Luo L, Na F, Li X, Huang Z, Ko JL, Mittal V, Qiao L, Chen C, Martinez FJ, Rafii S, Ding BS. Targeting the vascular and perivascular niches as a regenerative therapy for lung and liver fibrosis. Sci Transl Med. 2017 Aug 30; 9(405).
-
Ciccarese C, Brunelli M, Montironi R, Fiorentino M, Iacovelli R, Heng D, Tortora G, Massari F. The prospect of precision therapy for renal cell carcinoma. Cancer Treat Rev. 2016 Sep; 49:37-44.
-
Veenstra C, P?rez-Tenorio G, Stelling A, Karlsson E, Mirwani SM, Nordensk?ljd B, Fornander T, St?l O. Met and its ligand HGF are associated with clinical outcome in breast cancer. Oncotarget. 2016 Jun 14; 7(24):37145-37159.
-
Yin H, Bogorad RL, Barnes C, Walsh S, Zhuang I, Nonaka H, Ruda V, Kuchimanchi S, Nechev L, Akinc A, Xue W, Zerial M, Langer R, Anderson DG, Koteliansky V. RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver. J Hepatol. 2016 Apr; 64(4):899-907.
-
Smith BD, Kaufman MD, Leary CB, Turner BA, Wise SC, Ahn YM, Booth RJ, Caldwell TM, Ensinger CL, Hood MM, Lu WP, Patt TW, Patt WC, Rutkoski TJ, Samarakoon T, Telikepalli H, Vogeti L, Vogeti S, Yates KM, Chun L, Stewart LJ, Clare M, Flynn DL. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2. Mol Cancer Ther. 2015 Sep; 14(9):2023-34.
-
Lieb W, Chen MH, Larson MG, Safa R, Teumer A, Baumeister SE, Lin H, Smith HM, Koch M, Lorbeer R, V?lker U, Nauck M, V?lzke H, Wallaschofski H, Sawyer DB, Vasan RS. Genome-wide association study for endothelial growth factors. Circ Cardiovasc Genet. 2015 Apr; 8(2):389-97.
-
Kwon Y, Smith BD, Zhou Y, Kaufman MD, Godwin AK. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. Oncogene. 2015 Jan 08; 34(2):144-53.
-
Moon H, Cho S, Loh TJ, Zhou J, Ghigna C, Biamonti G, Green MR, Zheng X, Shen H. A 2-nt RNA enhancer on exon 11 promotes exon 11 inclusion of the Ron proto-oncogene. Oncol Rep. 2014 Jan; 31(1):450-5.